Phase 3, randomized, open and controlled study of a non-interferon regimen with active ingredient BI 207127 in combination with Fladaprevir and Ribavirin, compared to Telaprevir in combination with pegylated interferon alpha and ribavirin for the treatment of chronic hepatitis virus infection C (HCV) genotype 1b in patients without previous treatment
Boehringer Ingelheim AB
Pathology and candidate patients
Dr. Moises Diago
Hospital Quirónsalud Valencia.
BI 207127 in combination Fladaprevir and Ribavirin
June 13, 2013
Hospital Quirónsalud valencia
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment.
You can request a consultation with the cardiology team by sending an email to the address: firstname.lastname@example.org